MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Salmon, JS
Sandler, A
Billheimer, D
Herbst, RS
Tran, HT
Tsao, A
Dang, TP
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [31] Combination of Pitavastatin and Erlotinib Induces Apoptosis and Growth Arrest in Non-Small Cell Lung Cancer (NSCLC)-Celllines
    Minichsdorfer, Christoph
    Aydemir, Duygu
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S481 - S482
  • [32] Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC)
    Franzini, Anca
    Durr, Oliver
    Baty, Florent
    Brutsche, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [33] Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
    Chien, Chun-Ru
    Shih, Ya-Chen Tina
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 201 - 208
  • [34] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [35] Experience of erlotinib for non-small cell lung cancer (NSCLC) at the Exeter Oncology Centre
    Minear, F. G.
    Ward, A. J.
    Dorey, N. E.
    Osborne, M. E.
    Toy, E. W.
    LUNG CANCER, 2011, 71 : S8 - S8
  • [36] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [37] Cutaneous toxicity in erlotinib treatment for advanced non-small cell lung cancer (NSCLC)
    Bernabee, R.
    Cobo, M.
    Barneto, I.
    Valdivia, J.
    Fernandez, I.
    Rueda, A.
    Villatoro, R.
    de la Curz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Determinants of erlotinib and pemetrexed synergism in non-small cell lung cancer (NSCLC) cell lines
    Giovannetti, E.
    Smid, K.
    Tekie, C.
    Mey, V.
    Nannizzi, S.
    Rodriguez, J. A.
    Danesi, R.
    Del Tacca, M.
    Giaccone, G.
    Peters, G. J.
    ANNALS OF ONCOLOGY, 2007, 18 : 44 - 44
  • [39] Bevacizumab in Non-Small Cell Lung Cancer
    Francesco Di Costanzo
    Francesca Mazzoni
    Marinella Micol Mela
    Lorenzo Antonuzzo
    Daniele Checcacci
    Matilde Saggese
    Federica Di Costanzo
    Drugs, 2008, 68 : 737 - 746
  • [40] Bevacizumab in non-small cell lung cancer
    Di Costanzo, Francesco
    Mazzoni, Francesca
    Mela, Marinella Micol
    Antonuzzo, Lorenzo
    Checcacci, Daniele
    Saggese, Matilde
    Di Costanzo, Federica
    DRUGS, 2008, 68 (06) : 737 - 746
12345